nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.473	1	CbGbCtD
Ponatinib—FGFR3—appendage—amyotrophic lateral sclerosis	0.00971	0.0651	CbGeAlD
Ponatinib—FGFR4—hindbrain—amyotrophic lateral sclerosis	0.00755	0.0507	CbGeAlD
Ponatinib—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00588	0.0338	CcSEcCtD
Ponatinib—KDR—hindlimb—amyotrophic lateral sclerosis	0.0058	0.0389	CbGeAlD
Ponatinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00572	0.0329	CcSEcCtD
Ponatinib—KDR—appendage—amyotrophic lateral sclerosis	0.00498	0.0334	CbGeAlD
Ponatinib—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00492	0.0283	CcSEcCtD
Ponatinib—FGFR4—embryo—amyotrophic lateral sclerosis	0.00472	0.0317	CbGeAlD
Ponatinib—FGFR4—brainstem—amyotrophic lateral sclerosis	0.00433	0.029	CbGeAlD
Ponatinib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00421	0.0242	CcSEcCtD
Ponatinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00382	0.022	CcSEcCtD
Ponatinib—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00364	0.0209	CcSEcCtD
Ponatinib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00356	0.0204	CcSEcCtD
Ponatinib—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00356	0.0204	CcSEcCtD
Ponatinib—FGFR2—hindbrain—amyotrophic lateral sclerosis	0.00337	0.0226	CbGeAlD
Ponatinib—FGFR3—embryo—amyotrophic lateral sclerosis	0.00322	0.0216	CbGeAlD
Ponatinib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00322	0.0185	CcSEcCtD
Ponatinib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00309	0.0178	CcSEcCtD
Ponatinib—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00296	0.017	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0168	CcSEcCtD
Ponatinib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0168	CcSEcCtD
Ponatinib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00278	0.016	CcSEcCtD
Ponatinib—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00265	0.0152	CcSEcCtD
Ponatinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0146	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00244	0.014	CcSEcCtD
Ponatinib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00234	0.0157	CbGeAlD
Ponatinib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00234	0.0135	CcSEcCtD
Ponatinib—FGFR4—nervous system—amyotrophic lateral sclerosis	0.00227	0.0152	CbGeAlD
Ponatinib—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00225	0.0129	CcSEcCtD
Ponatinib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00224	0.0129	CcSEcCtD
Ponatinib—RET—embryo—amyotrophic lateral sclerosis	0.00222	0.0149	CbGeAlD
Ponatinib—FGFR4—central nervous system—amyotrophic lateral sclerosis	0.00218	0.0147	CbGeAlD
Ponatinib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0125	CcSEcCtD
Ponatinib—FGFR4—cerebellum—amyotrophic lateral sclerosis	0.00213	0.0143	CbGeAlD
Ponatinib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0123	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00212	0.0122	CcSEcCtD
Ponatinib—FGFR2—embryo—amyotrophic lateral sclerosis	0.00211	0.0142	CbGeAlD
Ponatinib—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00209	0.012	CcSEcCtD
Ponatinib—FGFR3—medulla oblongata—amyotrophic lateral sclerosis	0.00206	0.0138	CbGeAlD
Ponatinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0118	CcSEcCtD
Ponatinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00204	0.0137	CbGeAlD
Ponatinib—TEK—embryo—amyotrophic lateral sclerosis	0.00202	0.0136	CbGeAlD
Ponatinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0114	CcSEcCtD
Ponatinib—FGFR2—brainstem—amyotrophic lateral sclerosis	0.00193	0.013	CbGeAlD
Ponatinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0111	CcSEcCtD
Ponatinib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00192	0.011	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00191	0.011	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00187	0.0108	CcSEcCtD
Ponatinib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0106	CcSEcCtD
Ponatinib—FGFR3—spinal cord—amyotrophic lateral sclerosis	0.00184	0.0123	CbGeAlD
Ponatinib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.00183	0.0123	CbGeAlD
Ponatinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0103	CcSEcCtD
Ponatinib—SRC—embryo—amyotrophic lateral sclerosis	0.0018	0.0121	CbGeAlD
Ponatinib—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00179	0.0103	CcSEcCtD
Ponatinib—BCR—medulla oblongata—amyotrophic lateral sclerosis	0.00178	0.012	CbGeAlD
Ponatinib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0101	CcSEcCtD
Ponatinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.01	CcSEcCtD
Ponatinib—FGFR4—brain—amyotrophic lateral sclerosis	0.00173	0.0116	CbGeAlD
Ponatinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00986	CcSEcCtD
Ponatinib—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00972	CcSEcCtD
Ponatinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00954	CcSEcCtD
Ponatinib—KDR—embryo—amyotrophic lateral sclerosis	0.00165	0.0111	CbGeAlD
Ponatinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00946	CcSEcCtD
Ponatinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00941	CcSEcCtD
Ponatinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00941	CcSEcCtD
Ponatinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00927	CcSEcCtD
Ponatinib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00922	CcSEcCtD
Ponatinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00922	CcSEcCtD
Ponatinib—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00917	CcSEcCtD
Ponatinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00917	CcSEcCtD
Ponatinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00914	CcSEcCtD
Ponatinib—BCR—spinal cord—amyotrophic lateral sclerosis	0.00159	0.0107	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—amyotrophic lateral sclerosis	0.00159	0.0106	CbGeAlD
Ponatinib—LYN—nervous system—amyotrophic lateral sclerosis	0.00156	0.0104	CbGeAlD
Ponatinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0089	CcSEcCtD
Ponatinib—FGFR3—nervous system—amyotrophic lateral sclerosis	0.00155	0.0104	CbGeAlD
Ponatinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00887	CcSEcCtD
Ponatinib—LYN—central nervous system—amyotrophic lateral sclerosis	0.0015	0.01	CbGeAlD
Ponatinib—FGFR3—central nervous system—amyotrophic lateral sclerosis	0.00149	0.01	CbGeAlD
Ponatinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00849	CcSEcCtD
Ponatinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00844	CcSEcCtD
Ponatinib—KIT—embryo—amyotrophic lateral sclerosis	0.00146	0.00983	CbGeAlD
Ponatinib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0084	CcSEcCtD
Ponatinib—FGFR3—cerebellum—amyotrophic lateral sclerosis	0.00146	0.00977	CbGeAlD
Ponatinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00832	CcSEcCtD
Ponatinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0083	CcSEcCtD
Ponatinib—RET—medulla oblongata—amyotrophic lateral sclerosis	0.00142	0.00952	CbGeAlD
Ponatinib—FGFR1—spinal cord—amyotrophic lateral sclerosis	0.00141	0.00949	CbGeAlD
Ponatinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00789	CcSEcCtD
Ponatinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00784	CcSEcCtD
Ponatinib—KIT—brainstem—amyotrophic lateral sclerosis	0.00134	0.00901	CbGeAlD
Ponatinib—BCR—nervous system—amyotrophic lateral sclerosis	0.00134	0.00899	CbGeAlD
Ponatinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00766	CcSEcCtD
Ponatinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00761	CcSEcCtD
Ponatinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00758	CcSEcCtD
Ponatinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00754	CcSEcCtD
Ponatinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00746	CcSEcCtD
Ponatinib—TEK—medulla oblongata—amyotrophic lateral sclerosis	0.00129	0.00867	CbGeAlD
Ponatinib—BCR—central nervous system—amyotrophic lateral sclerosis	0.00129	0.00865	CbGeAlD
Ponatinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00129	0.0074	CcSEcCtD
Ponatinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00735	CcSEcCtD
Ponatinib—ABL1—embryo—amyotrophic lateral sclerosis	0.00128	0.00856	CbGeAlD
Ponatinib—RET—spinal cord—amyotrophic lateral sclerosis	0.00127	0.00849	CbGeAlD
Ponatinib—BCR—cerebellum—amyotrophic lateral sclerosis	0.00126	0.00846	CbGeAlD
Ponatinib—FLT3—cerebellum—amyotrophic lateral sclerosis	0.00125	0.0084	CbGeAlD
Ponatinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00711	CcSEcCtD
Ponatinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00707	CcSEcCtD
Ponatinib—FGFR2—spinal cord—amyotrophic lateral sclerosis	0.0012	0.00807	CbGeAlD
Ponatinib—LYN—brain—amyotrophic lateral sclerosis	0.00119	0.00798	CbGeAlD
Ponatinib—FGFR3—brain—amyotrophic lateral sclerosis	0.00118	0.00794	CbGeAlD
Ponatinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00679	CcSEcCtD
Ponatinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.00117	0.00784	CbGeAlD
Ponatinib—TEK—spinal cord—amyotrophic lateral sclerosis	0.00115	0.00773	CbGeAlD
Ponatinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00658	CcSEcCtD
Ponatinib—FGFR1—cerebellum—amyotrophic lateral sclerosis	0.00112	0.00752	CbGeAlD
Ponatinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00641	CcSEcCtD
Ponatinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00635	CcSEcCtD
Ponatinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00626	CcSEcCtD
Ponatinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00626	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00621	CcSEcCtD
Ponatinib—RET—nervous system—amyotrophic lateral sclerosis	0.00107	0.00715	CbGeAlD
Ponatinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00612	CcSEcCtD
Ponatinib—KDR—medulla oblongata—amyotrophic lateral sclerosis	0.00106	0.00709	CbGeAlD
Ponatinib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.00104	0.00701	CbGeAlD
Ponatinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00104	0.006	CcSEcCtD
Ponatinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00596	CcSEcCtD
Ponatinib—RET—central nervous system—amyotrophic lateral sclerosis	0.00103	0.00689	CbGeAlD
Ponatinib—SRC—spinal cord—amyotrophic lateral sclerosis	0.00102	0.00687	CbGeAlD
Ponatinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00588	CcSEcCtD
Ponatinib—BCR—brain—amyotrophic lateral sclerosis	0.00102	0.00687	CbGeAlD
Ponatinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00587	CcSEcCtD
Ponatinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00583	CcSEcCtD
Ponatinib—FGFR2—nervous system—amyotrophic lateral sclerosis	0.00101	0.0068	CbGeAlD
Ponatinib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0058	CcSEcCtD
Ponatinib—RET—cerebellum—amyotrophic lateral sclerosis	0.001	0.00673	CbGeAlD
Ponatinib—FGFR2—central nervous system—amyotrophic lateral sclerosis	0.000975	0.00654	CbGeAlD
Ponatinib—TEK—nervous system—amyotrophic lateral sclerosis	0.000971	0.00652	CbGeAlD
Ponatinib—FGFR2—cerebellum—amyotrophic lateral sclerosis	0.000953	0.0064	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00547	CcSEcCtD
Ponatinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000944	0.00543	CcSEcCtD
Ponatinib—KDR—spinal cord—amyotrophic lateral sclerosis	0.000942	0.00632	CbGeAlD
Ponatinib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000937	0.00539	CcSEcCtD
Ponatinib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000936	0.00628	CbGeAlD
Ponatinib—TEK—central nervous system—amyotrophic lateral sclerosis	0.000935	0.00627	CbGeAlD
Ponatinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000931	0.00535	CcSEcCtD
Ponatinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000919	0.00528	CcSEcCtD
Ponatinib—TEK—cerebellum—amyotrophic lateral sclerosis	0.000914	0.00613	CbGeAlD
Ponatinib—FGFR1—brain—amyotrophic lateral sclerosis	0.000911	0.00611	CbGeAlD
Ponatinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000907	0.00521	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00518	CcSEcCtD
Ponatinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0009	0.00517	CcSEcCtD
Ponatinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00513	CcSEcCtD
Ponatinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00513	CcSEcCtD
Ponatinib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000881	0.00592	CbGeAlD
Ponatinib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.00088	0.0059	CbGeAlD
Ponatinib—SRC—nervous system—amyotrophic lateral sclerosis	0.000863	0.00579	CbGeAlD
Ponatinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00491	CcSEcCtD
Ponatinib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000847	0.00568	CbGeAlD
Ponatinib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000835	0.0056	CbGeAlD
Ponatinib—SRC—central nervous system—amyotrophic lateral sclerosis	0.000831	0.00557	CbGeAlD
Ponatinib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000828	0.00556	CbGeAlD
Ponatinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000825	0.00474	CcSEcCtD
Ponatinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000825	0.00474	CcSEcCtD
Ponatinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000815	0.00547	CbGeAlD
Ponatinib—RET—brain—amyotrophic lateral sclerosis	0.000815	0.00547	CbGeAlD
Ponatinib—SRC—cerebellum—amyotrophic lateral sclerosis	0.000812	0.00545	CbGeAlD
Ponatinib—KDR—nervous system—amyotrophic lateral sclerosis	0.000794	0.00533	CbGeAlD
Ponatinib—FGFR2—brain—amyotrophic lateral sclerosis	0.000774	0.0052	CbGeAlD
Ponatinib—KDR—central nervous system—amyotrophic lateral sclerosis	0.000764	0.00513	CbGeAlD
Ponatinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000749	0.0043	CcSEcCtD
Ponatinib—KDR—cerebellum—amyotrophic lateral sclerosis	0.000747	0.00501	CbGeAlD
Ponatinib—TEK—brain—amyotrophic lateral sclerosis	0.000742	0.00498	CbGeAlD
Ponatinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000738	0.00424	CcSEcCtD
Ponatinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000727	0.00488	CbGeAlD
Ponatinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000714	0.0041	CcSEcCtD
Ponatinib—KIT—nervous system—amyotrophic lateral sclerosis	0.000703	0.00472	CbGeAlD
Ponatinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00069	0.00397	CcSEcCtD
Ponatinib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000677	0.00454	CbGeAlD
Ponatinib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000672	0.00451	CbGeAlD
Ponatinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000664	0.00381	CcSEcCtD
Ponatinib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000662	0.00444	CbGeAlD
Ponatinib—SRC—brain—amyotrophic lateral sclerosis	0.000659	0.00443	CbGeAlD
Ponatinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000658	0.00378	CcSEcCtD
Ponatinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000658	0.00378	CcSEcCtD
Ponatinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000654	0.00376	CcSEcCtD
Ponatinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00356	CcSEcCtD
Ponatinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000612	0.00411	CbGeAlD
Ponatinib—KDR—brain—amyotrophic lateral sclerosis	0.000607	0.00407	CbGeAlD
Ponatinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000589	0.00396	CbGeAlD
Ponatinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000576	0.00387	CbGeAlD
Ponatinib—KIT—brain—amyotrophic lateral sclerosis	0.000538	0.00361	CbGeAlD
Ponatinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000514	0.00345	CbGeAlD
Ponatinib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000505	0.00339	CbGeAlD
Ponatinib—ABL1—brain—amyotrophic lateral sclerosis	0.000468	0.00314	CbGeAlD
Ponatinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000458	0.00308	CbGeAlD
Ponatinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000397	0.00266	CbGeAlD
Ponatinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000363	0.00244	CbGeAlD
Ponatinib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000304	0.00204	CbGeAlD
Ponatinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000295	0.00198	CbGeAlD
Ponatinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000269	0.00181	CbGeAlD
Ponatinib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000265	0.00178	CbGeAlD
Ponatinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000259	0.00174	CbGeAlD
Ponatinib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000255	0.00171	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000253	0.0017	CbGeAlD
Ponatinib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000249	0.00167	CbGeAlD
Ponatinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000226	0.00152	CbGeAlD
Ponatinib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000202	0.00136	CbGeAlD
Ponatinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00019	0.00128	CbGeAlD
Ponatinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000183	0.00123	CbGeAlD
Ponatinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000179	0.0012	CbGeAlD
Ponatinib—ABCB1—brain—amyotrophic lateral sclerosis	0.000146	0.000977	CbGeAlD
Ponatinib—KIT—Immune System—CD40LG—amyotrophic lateral sclerosis	3.01e-05	0.000148	CbGpPWpGaD
Ponatinib—FGFR2—Disease—ERBB4—amyotrophic lateral sclerosis	3.01e-05	0.000148	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	3.01e-05	0.000148	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—C3—amyotrophic lateral sclerosis	3e-05	0.000147	CbGpPWpGaD
Ponatinib—SRC—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	3e-05	0.000147	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.96e-05	0.000145	CbGpPWpGaD
Ponatinib—KIT—Disease—ERBB4—amyotrophic lateral sclerosis	2.96e-05	0.000145	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.96e-05	0.000145	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.96e-05	0.000145	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.94e-05	0.000144	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.89e-05	0.000142	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.88e-05	0.000141	CbGpPWpGaD
Ponatinib—SRC—Disease—CST3—amyotrophic lateral sclerosis	2.88e-05	0.000141	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	2.87e-05	0.000141	CbGpPWpGaD
Ponatinib—LCK—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.87e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.86e-05	0.00014	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD40LG—amyotrophic lateral sclerosis	2.85e-05	0.00014	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.81e-05	0.000138	CbGpPWpGaD
Ponatinib—FGFR1—Disease—ERBB4—amyotrophic lateral sclerosis	2.81e-05	0.000138	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—ERBB4—amyotrophic lateral sclerosis	2.8e-05	0.000137	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.77e-05	0.000136	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—C3—amyotrophic lateral sclerosis	2.77e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.76e-05	0.000135	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.75e-05	0.000135	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.74e-05	0.000134	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.73e-05	0.000134	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.73e-05	0.000134	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.72e-05	0.000133	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—C3—amyotrophic lateral sclerosis	2.71e-05	0.000133	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.71e-05	0.000133	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.7e-05	0.000132	CbGpPWpGaD
Ponatinib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	2.69e-05	0.000132	CbGpPWpGaD
Ponatinib—LYN—Immune System—ERBB4—amyotrophic lateral sclerosis	2.67e-05	0.000131	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.67e-05	0.000131	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.67e-05	0.000131	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.66e-05	0.000131	CbGpPWpGaD
Ponatinib—KIT—Immune System—C3—amyotrophic lateral sclerosis	2.66e-05	0.000131	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—C3—amyotrophic lateral sclerosis	2.66e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.65e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.59e-05	0.000127	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.57e-05	0.000126	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.56e-05	0.000126	CbGpPWpGaD
Ponatinib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	2.56e-05	0.000126	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.56e-05	0.000126	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.55e-05	0.000125	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.55e-05	0.000125	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.54e-05	0.000125	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.54e-05	0.000125	CbGpPWpGaD
Ponatinib—SRC—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.54e-05	0.000124	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.53e-05	0.000124	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—C3—amyotrophic lateral sclerosis	2.53e-05	0.000124	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—C3—amyotrophic lateral sclerosis	2.52e-05	0.000124	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD40LG—amyotrophic lateral sclerosis	2.51e-05	0.000123	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.51e-05	0.000123	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.51e-05	0.000123	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.51e-05	0.000123	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.5e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.47e-05	0.000121	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.46e-05	0.000121	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.46e-05	0.000121	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.46e-05	0.00012	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.42e-05	0.000119	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.42e-05	0.000119	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.42e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.41e-05	0.000118	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.41e-05	0.000118	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.41e-05	0.000118	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.39e-05	0.000117	CbGpPWpGaD
Ponatinib—SRC—Immune System—ATF1—amyotrophic lateral sclerosis	2.38e-05	0.000117	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.37e-05	0.000116	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.37e-05	0.000116	CbGpPWpGaD
Ponatinib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	2.36e-05	0.000116	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	2.36e-05	0.000116	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.35e-05	0.000115	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.34e-05	0.000115	CbGpPWpGaD
Ponatinib—FGFR2—Disease—APOE—amyotrophic lateral sclerosis	2.33e-05	0.000114	CbGpPWpGaD
Ponatinib—FGFR3—Disease—PTGS2—amyotrophic lateral sclerosis	2.32e-05	0.000114	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.3e-05	0.000113	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.29e-05	0.000112	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.29e-05	0.000112	CbGpPWpGaD
Ponatinib—KIT—Disease—APOE—amyotrophic lateral sclerosis	2.29e-05	0.000112	CbGpPWpGaD
Ponatinib—SRC—Immune System—CASP9—amyotrophic lateral sclerosis	2.27e-05	0.000111	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.26e-05	0.000111	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	2.24e-05	0.00011	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.23e-05	0.000109	CbGpPWpGaD
Ponatinib—LYN—Immune System—C3—amyotrophic lateral sclerosis	2.22e-05	0.000109	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.22e-05	0.000109	CbGpPWpGaD
Ponatinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	2.21e-05	0.000108	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.21e-05	0.000108	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	2.19e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR1—Disease—APOE—amyotrophic lateral sclerosis	2.17e-05	0.000106	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.17e-05	0.000106	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	2.17e-05	0.000106	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.16e-05	0.000106	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.15e-05	0.000106	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.13e-05	0.000105	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.13e-05	0.000104	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.12e-05	0.000104	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.12e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.11e-05	0.000103	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.1e-05	0.000103	CbGpPWpGaD
Ponatinib—SRC—Disease—CASP9—amyotrophic lateral sclerosis	2.09e-05	0.000103	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.07e-05	0.000102	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.07e-05	0.000101	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	2.06e-05	0.000101	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	2.06e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.04e-05	0.0001	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	2.02e-05	9.93e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.02e-05	9.91e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2e-05	9.83e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.99e-05	9.77e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.98e-05	9.72e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.97e-05	9.64e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.96e-05	9.61e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.96e-05	9.61e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.95e-05	9.55e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB4—amyotrophic lateral sclerosis	1.94e-05	9.52e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.94e-05	9.51e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.94e-05	9.51e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.93e-05	9.45e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—APOE—amyotrophic lateral sclerosis	1.92e-05	9.42e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.86e-05	9.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.85e-05	9.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.85e-05	9.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.84e-05	9.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD40LG—amyotrophic lateral sclerosis	1.82e-05	8.95e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.82e-05	8.93e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.81e-05	8.89e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB4—amyotrophic lateral sclerosis	1.79e-05	8.79e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.77e-05	8.68e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.75e-05	8.6e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.75e-05	8.59e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.75e-05	8.56e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.74e-05	8.53e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.73e-05	8.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.73e-05	8.48e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.72e-05	8.44e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.71e-05	8.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.69e-05	8.29e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.68e-05	8.24e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.66e-05	8.12e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.64e-05	8.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.63e-05	8.01e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.63e-05	8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.63e-05	7.99e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.63e-05	7.97e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—C3—amyotrophic lateral sclerosis	1.61e-05	7.91e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—amyotrophic lateral sclerosis	1.61e-05	7.89e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.6e-05	7.86e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.6e-05	7.85e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTGS2—amyotrophic lateral sclerosis	1.6e-05	7.83e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.59e-05	7.81e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.58e-05	7.72e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	1.57e-05	7.69e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	1.57e-05	7.68e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.55e-05	7.58e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.54e-05	7.57e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.54e-05	7.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.52e-05	7.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.52e-05	7.44e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.51e-05	7.4e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.51e-05	7.39e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTGS2—amyotrophic lateral sclerosis	1.49e-05	7.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	1.48e-05	7.28e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.47e-05	7.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.44e-05	7.05e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.43e-05	6.99e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.42e-05	6.95e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APOE—amyotrophic lateral sclerosis	1.39e-05	6.8e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.37e-05	6.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.35e-05	6.61e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.34e-05	6.56e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	6.54e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.32e-05	6.49e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	1.32e-05	6.47e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.32e-05	6.46e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.31e-05	6.44e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.31e-05	6.41e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.28e-05	6.28e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.27e-05	6.23e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.27e-05	6.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.26e-05	6.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.25e-05	6.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.25e-05	6.15e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.24e-05	6.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.21e-05	5.95e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.2e-05	5.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.18e-05	5.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.18e-05	5.78e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—amyotrophic lateral sclerosis	1.17e-05	5.73e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.12e-05	5.47e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.11e-05	5.42e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.11e-05	5.42e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.1e-05	5.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	1.07e-05	5.26e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.04e-05	5.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.04e-05	5.11e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.04e-05	5.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.04e-05	5.09e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.02e-05	5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.81e-06	4.81e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.71e-06	4.76e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.67e-06	4.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.67e-06	4.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.65e-06	4.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.63e-06	4.72e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.58e-06	4.7e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—amyotrophic lateral sclerosis	9.5e-06	4.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.14e-06	4.48e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.12e-06	4.47e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	9.1e-06	4.46e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.08e-06	4.45e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.06e-06	4.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.81e-06	4.32e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.7e-06	4.27e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.65e-06	4.24e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.56e-06	4.2e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.51e-06	4.17e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.43e-06	4.13e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.35e-06	4.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.21e-06	4.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.19e-06	4.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.04e-06	3.94e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.02e-06	3.93e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	7.88e-06	3.87e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.87e-06	3.86e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.22e-06	3.54e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.97e-06	3.42e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	6.87e-06	3.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.65e-06	3.26e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.59e-06	3.23e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.53e-06	3.2e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	6.47e-06	3.17e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.24e-06	3.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.2e-06	3.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.19e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.17e-06	3.03e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.92e-06	2.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.83e-06	2.86e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.6e-06	2.74e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.46e-06	2.68e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.4e-06	2.65e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.24e-06	2.57e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.14e-06	2.52e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.71e-06	2.31e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.47e-06	2.19e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.43e-06	2.17e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.23e-06	2.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.96e-06	1.94e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.9e-06	1.42e-05	CbGpPWpGaD
